A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
NCT07459647
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
500
Enrollment
INDUSTRY
Sponsor class
Conditions
Schizophrenia
Interventions
DRUG:
ML-007C-MA
Sponsor
MapLight Therapeutics